絞り込み

16735

広告

目前に迫った首都圏の感染爆発に備えよ (日経BP)

首都圏における新型コロナウイルス感染症(COVID-19)の患者数増加が止まらない。4月1日の時点で東京都の感染者数は587人となり、オーバーシュート(爆発的な...

  1. 60歳代男性。肺癌検診 (日経BP)
  2. 「限りある医療資源の選択的配分」について...
  3. COVID-19流行中の癌治療をどうする...
  4. 外科系学会、COVID-19患者・疑い例...

ニュース一覧

Complex Decisions for First-Line and Maintenance Treatment of Advanced Wild-Type Non-Small Cell Lung Cancer.

著者 Gentzler RD , Johnson ML
Oncologist.2015 Feb 6 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (5,354view , 1users)

Full Text Sources

Medical

Until recently, the first-line treatment of advanced non-small cell lung cancer (NSCLC) required minimal clinical decision making. Patients who were eligible for chemotherapy received a platinum-based doublet, and 5-year survival rates were poor. With the advent of molecularly targeted agents and better tolerated chemotherapies-namely, bevacizumab, erlotinib, and pemetrexed-new therapeutic opportunities have emerged. Some of the strategies that have proven to be successful for the treatment of patients with NSCLC are targeting of the vascular endothelial growth factor, use of maintenance chemotherapy for patients without progression of disease after initial therapy, and tailoring of cytotoxic agents specific to the histology of an individual patient's cancer. Each approach has been independently shown to improve overall survival, but integrating the data from a number of complicated trials into the "best" approach for patients remains challenging. This review attempts to address three fundamental questions clinicians face in choosing first-line and maintenance treatment for advanced NSCLC, particularly nonsquamous histology: Is pemetrexed or a taxane agent better for combination with platinum therapy? Should bevacizumab be used, and is it beneficial when added to pemetrexed chemotherapy? When is maintenance therapy indicated, and which agent is best?
PMID: 25660158 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード